2 news items
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
SAVA
10 May 24
of independent clinical research experts who periodically review interim patient safety data. Routine, scheduled DSMB meetings were held September 2023
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
SAVA
25 Mar 24
." The DSMB is composed of independent clinical research experts who periodically review interim patient safety data for Cassava Sciences' on-going
- Prev
- 1
- Next